# A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer

> **NCT03728556** · PHASE3 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 381 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer Stage III

## Interventions

- **BIOLOGICAL:** CS1001 monoclonal antibody
- **BIOLOGICAL:** CS1001 placebo

## Key facts

- **NCT ID:** NCT03728556
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-26
- **Primary completion:** 2023-04-03
- **Final completion:** 2023-04-03
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2023-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03728556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03728556, "A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03728556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*